EXEL News and Press, Exelixis Inc. From 11/09/21

– Global, phase 3 pivotal trial part of ongoing clinical collaboration with Roche – Exelixis, Inc. (Nasdaq: EXEL) today announced that enrollment is now completed for CONTACT-01, the global, phase 3 pivotal trial evaluating cabozantinib (CABOMETYX ® ...

Some investing decisions are really hard to make. Others, though, can be quick and easy. That's the case when the stocks offer compelling growth prospects that are undeniable. We asked three Motley Fool contributors to pick no-brainer biotech stocks to buy in November. Here's why th...

- Presentations to be webcast on www.exelixis.com - Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following virtual investor conferences in November and December of 2021: ...

Gainers: Petros Pharmaceuticals (NASDAQ:PTPI) +110%, iRhythm Technologies IRTC +44%, Karyopharm Therapeutics KPTI +31%, Glaukos GKOS +25%, Rafael RFL +15%. Losers: Cardiol Therapeutics CRDL -25%, Bone Biologics (OTCPK:BBLG) -15%, ...

The following slide deck was published by Exelixis, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Exelixis, Inc. 2021 Q3 - Results - Earnings Call Presentation

Image source: The Motley Fool. Exelixis, inc (NASDAQ: EXEL) Q3 2021 Earnings Call Nov 2, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Exelixis, inc (EXEL) Q3 2021 Earnings Call Transcript

Exelixis, Inc. (EXEL) Q3 2021 Earnings Conference Call November 02, 2021, 17:00 PM ET Company Participants Susan Hubbard - Executive Vice President, Public Affairs & Investor Relations Michael Morrissey - President and Chief Executive Officer Christopher Senner - Executive Vice President ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The biotech world — and especially retail investors who follow it — has been closely tracking Cassava Sciences (NASDAQ: SAVA ) in recent weeks. This comes as its Alzheimer’s drug Simufilam continu...

Exelixis (NASDAQ:EXEL) shares slide more than 8% post market after the company reported third-quarter revenue that missed Wall Street estimates. Quarterly revenue increased $328.4M, falling short of analysts' estimate by $28.66M. The increase in net product revenues was primarily related...

Exelixis (NASDAQ:EXEL): Q3 Non-GAAP EPS of $0.20 beats by $0.02; GAAP EPS of $0.12 misses by $0.06. Revenue of $328.4M (+42.1% Y/Y) misses by $28.66M. Shares -6%. Press Release FY21 outlook: Revenue $1.3B-$1.35B vs. $1.39B consensus. Cash and investments $1.8B Net product revenues $1,050...